JP2008504257A5 - - Google Patents

Download PDF

Info

Publication number
JP2008504257A5
JP2008504257A5 JP2007518098A JP2007518098A JP2008504257A5 JP 2008504257 A5 JP2008504257 A5 JP 2008504257A5 JP 2007518098 A JP2007518098 A JP 2007518098A JP 2007518098 A JP2007518098 A JP 2007518098A JP 2008504257 A5 JP2008504257 A5 JP 2008504257A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
pharmaceutically acceptable
related macular
macular degeneration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007518098A
Other languages
English (en)
Japanese (ja)
Other versions
JP4855396B2 (ja
JP2008504257A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/020080 external-priority patent/WO2006007314A1/en
Publication of JP2008504257A publication Critical patent/JP2008504257A/ja
Publication of JP2008504257A5 publication Critical patent/JP2008504257A5/ja
Application granted granted Critical
Publication of JP4855396B2 publication Critical patent/JP4855396B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007518098A 2004-06-23 2005-06-06 レチナール誘導体で眼科的な状態を処置するための方法および組成物 Expired - Fee Related JP4855396B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US58229304P 2004-06-23 2004-06-23
US60/582,293 2004-06-23
US62969504P 2004-11-19 2004-11-19
US60/629,695 2004-11-19
US66090405P 2005-03-11 2005-03-11
US60/660,904 2005-03-11
US67240505P 2005-04-18 2005-04-18
US60/672,405 2005-04-18
PCT/US2005/020080 WO2006007314A1 (en) 2004-06-23 2005-06-06 Methods and compositions for treating ophthalmic conditions with retinyl derivatives

Publications (3)

Publication Number Publication Date
JP2008504257A JP2008504257A (ja) 2008-02-14
JP2008504257A5 true JP2008504257A5 (enExample) 2008-07-10
JP4855396B2 JP4855396B2 (ja) 2012-01-18

Family

ID=34981643

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007518098A Expired - Fee Related JP4855396B2 (ja) 2004-06-23 2005-06-06 レチナール誘導体で眼科的な状態を処置するための方法および組成物

Country Status (26)

Country Link
US (3) US8314152B2 (enExample)
EP (3) EP1768657B1 (enExample)
JP (1) JP4855396B2 (enExample)
KR (1) KR100862930B1 (enExample)
AR (1) AR049929A1 (enExample)
AT (1) ATE404188T1 (enExample)
AU (1) AU2005262558B8 (enExample)
BR (1) BRPI0512569A (enExample)
CA (1) CA2569691C (enExample)
CY (1) CY1110435T1 (enExample)
DE (1) DE602005008970D1 (enExample)
DK (1) DK1768657T3 (enExample)
EA (1) EA011864B1 (enExample)
ES (1) ES2313368T3 (enExample)
GE (1) GEP20084520B (enExample)
IL (1) IL179872A (enExample)
LV (1) LV13564B (enExample)
MX (1) MXPA06014978A (enExample)
NO (1) NO20070408L (enExample)
NZ (1) NZ551955A (enExample)
PL (1) PL1768657T3 (enExample)
PT (1) PT1768657E (enExample)
SG (1) SG140607A1 (enExample)
SI (1) SI1768657T1 (enExample)
TW (1) TWI396532B (enExample)
WO (1) WO2006007314A1 (enExample)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2327401A3 (en) 2003-03-14 2011-10-19 University of Washington Retinoid Replacements and Opsin Agonists and Methods for the Use Thereof
PL380611A1 (pl) 2004-02-17 2007-02-19 President And Fellows Of Harvard College Postępowanie z zaburzeniami oftalmologicznymi, włącznie ze zwyrodnieniem plamki
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
JP2007525496A (ja) * 2004-02-17 2007-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 黄班変性症を含む眼科疾患の管理
PL2397133T3 (pl) 2004-06-18 2018-01-31 Univ Washington Pochodne retinalu i sposoby ich zastosowania do leczenia zaburzeń wzroku
PL1768657T3 (pl) 2004-06-23 2009-01-30 Revision Therapeutics Inc Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
US20060089411A1 (en) * 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
WO2006033734A2 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
EP1804771A2 (en) * 2004-10-28 2007-07-11 Idexx Laboratories, Inc. Compositions for controlled delivery of pharmaceutically active compounds
JP2008519054A (ja) * 2004-11-04 2008-06-05 シリオン セラピューティクス， インコーポレイテッド レチノール−レチノール結合タンパク質（ｒｂｐ）−トランスチレチン（ｔｔｒ）複合体の形成のモジュレーター
BRPI0520207A2 (pt) * 2004-12-08 2012-09-25 Revision Therapeutics Inc uso de uma quantidade eficaz de um primeiro composto, e, medicamento sistemicamente formulado
UA81382C2 (en) * 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
US8114440B2 (en) * 2005-11-16 2012-02-14 Idexx Laboratories Inc. Pharmaceutical compositions for the administration of aptamers
US7754679B2 (en) * 2005-11-16 2010-07-13 Idexx Laboratories, Inc. Pharmaceutical compositions for the administration of aptamers
EP2037951A2 (en) * 2006-06-22 2009-03-25 Sirion Therapeutics, Inc. Methods and compositions for treating ophthalmic conditions via modulation of megalin activity
AU2007277032A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Opsin stabilizing compounds and methods of use
CA2657164A1 (en) * 2006-07-27 2008-01-31 University Of Florida Research Foundation, Inc. Compositions and methods for treating or preventing ophthalmic light toxicity
EP2069391A4 (en) * 2006-07-27 2009-12-30 Univ Florida COMPOSITIONS AND METHODS FOR TREATING AND / OR PREVENTING OPHTHALMOLOGICAL DISEASES
US8828960B2 (en) * 2007-07-17 2014-09-09 Idexx Laboratories, Inc. Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds
MX337656B (es) 2008-02-11 2016-03-14 Univ Washington Metodos para el tratamiento y prevencion de disfuncion retinal relacionada con la edad.
WO2009114136A2 (en) * 2008-03-12 2009-09-17 Albert Einstein College Of Medicine Of Yeshiva University Fenretinide derivatives and uses thereof as therapeutic, diagnostic and imaging agents
MX2011000545A (es) * 2008-07-14 2011-02-24 Otonomy Inc Composiciones de liberacion controlada para la modulacion de apoptosis y metodos para el tratamiento de trastornos oticos.
EP2427052B1 (en) * 2009-05-04 2015-08-26 Acucela, Inc. Compositions for use in the treatment of glaucoma or ocular hypertension
IN2012DN00352A (enExample) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
RU2546005C2 (ru) 2009-09-15 2015-04-10 Кью Эл Ти ИНК. Фармацевтические составы, содержащие 9-цис-ретиниловые сложные эфиры в липидном наполнителе
ES2758554T3 (es) 2009-12-08 2020-05-05 Univ Case Western Reserve Aminoácidos gama para tratamiento de trastornos oculares
US9173856B2 (en) * 2010-04-19 2015-11-03 Qlt Inc. Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
WO2013082000A1 (en) 2011-11-30 2013-06-06 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US10058616B2 (en) * 2012-02-10 2018-08-28 Tlc Biopharmaceuticals, Inc. Pharmaceutical compositions to reduce complications of ocular steroid
CN104470511A (zh) 2012-03-01 2015-03-25 Qlt股份有限公司 用于在与内源性维甲酸类缺乏相关的视觉障碍中改善视觉功能的治疗方案和方法
US9011845B2 (en) 2012-06-26 2015-04-21 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods for treatment of inflammatory and infectious viral diseases
US8877183B2 (en) 2012-06-26 2014-11-04 National Institutes Of Health (Nih) Methods for treatment of ocular diseases
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
US10092393B2 (en) 2013-03-14 2018-10-09 Allotex, Inc. Corneal implant systems and methods
US10471118B2 (en) * 2014-05-30 2019-11-12 Case Western Reserve University Retinylamine derivitives for treatment of ocular disorders
MY183209A (en) 2014-10-24 2021-02-18 Takeda Pharmaceuticals Co Heterocyclic compound
US10327946B2 (en) * 2014-12-19 2019-06-25 Kemin Industries, Inc. Intraocular delivery of bioactive molecules using iontophoresis
US10449090B2 (en) 2015-07-31 2019-10-22 Allotex, Inc. Corneal implant systems and methods
PL3416622T3 (pl) * 2016-02-15 2023-09-11 Kemin Industries, Inc. Dodatnio naładowane liposomy jako nośniki cząsteczek lipofilowych
US11395853B2 (en) 2016-06-23 2022-07-26 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Biomimetic drug delivery of an immunomodulatory agent for the treatment of ocular conditions
WO2018106594A2 (en) * 2016-12-05 2018-06-14 The Jackson Laboratory Fat droplets in retina and optic nerve as a diagnostic marker for neurodegeneration and glaucoma in humans
JP7163288B2 (ja) * 2017-07-04 2022-10-31 第一三共株式会社 視細胞変性を伴う網膜変性疾患用薬
BR112021022270A2 (pt) * 2019-05-06 2022-01-11 Univ California Materiais e métodos para tratar degeneração macular relacionada à idade
FR3105790B1 (fr) * 2019-12-26 2022-01-14 Biophytis Composés chimiques ciblant l’œil et leur utilisation dans le traitement de maladies oculaires

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190594A (en) 1975-11-03 1980-02-26 Johnson & Johnson Retinoic acid derivatives
US4323581A (en) 1978-07-31 1982-04-06 Johnson & Johnson Method of treating carcinogenesis
US4665098A (en) 1985-03-28 1987-05-12 Mcneilab, Inc. Pharmaceutical composition of N-(4-hydroxyphenyl) retinamide having increased bioavailability
US4874795A (en) 1985-04-02 1989-10-17 Yesair David W Composition for delivery of orally administered drugs and other substances
US4673044A (en) * 1985-08-02 1987-06-16 Eastman Christensen Co. Earth boring bit for soft to hard formations
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4682663A (en) * 1986-02-18 1987-07-28 Reed Tool Company Mounting means for cutting elements in drag type rotary drill bit
US4743400A (en) 1986-09-22 1988-05-10 Mcneilab, Inc. Process for preparing retinoyl chlorides
WO1991001745A1 (en) 1989-07-28 1991-02-21 Sloan-Kettering Institute For Cancer Research Growth factors containing vitamin a or other retinoids and uses thereof
US5814612A (en) 1991-04-09 1998-09-29 Sloan-Kettering Institute For Cancer Research Retinol derivatives and uses thereof
US6506917B1 (en) 1991-12-18 2003-01-14 The Salk Institute For Biological Studies Compounds and compositions useful for modulation of processes mediated by RXR
US6050354A (en) * 1992-01-31 2000-04-18 Baker Hughes Incorporated Rolling cutter bit with shear cutting gage
US5314909A (en) 1993-03-17 1994-05-24 Merck & Co., Inc. Use of non-steroidal antiiflammatory agents in macular degeneration
US5399757A (en) 1993-07-20 1995-03-21 Ortho Pharmaceutical Corporation Process for the preparation of N-(4-hydroxyphenyl)-retinamide
US5824685A (en) 1995-02-01 1998-10-20 The Johns Hopkins University School Of Medicine Method of preventing proliferation of retinal pigment epithelium by retinoic acid receptor agonists
US5596011A (en) 1995-04-06 1997-01-21 Repine; Karen M. Method for the treatment of macular degeneration
US5702357A (en) * 1995-06-07 1997-12-30 Cobe Laboratories, Inc. Extracorporeal blood processing methods and apparatus
US5706906A (en) * 1996-02-15 1998-01-13 Baker Hughes Incorporated Superabrasive cutting element with enhanced durability and increased wear life, and apparatus so equipped
US5758733A (en) * 1996-04-17 1998-06-02 Baker Hughes Incorporated Earth-boring bit with super-hard cutting elements
US5846220A (en) 1996-04-30 1998-12-08 Medtronic, Inc. Therapeutic method for treatment of Alzheimer's disease
US6034211A (en) 1996-06-03 2000-03-07 Kelly; Jeffery W. β-sheet nucleating peptidomimetics
GB9621217D0 (en) * 1996-10-11 1996-11-27 Camco Drilling Group Ltd Improvements in or relating to preform cutting elements for rotary drill bits
WO1998027972A2 (en) 1996-12-23 1998-07-02 Texas A & M University Anti-amyloidogenic agents
US5955305A (en) 1997-04-28 1999-09-21 Incyte Pharmaceuticals, Inc. Human retinoid binding protein
US5776915A (en) 1997-08-12 1998-07-07 Clarion Pharmaceuticals Inc. Phosphocholines of retinoids
PL338555A1 (en) 1997-08-15 2000-11-06 Univ Duke Method of preventing or treating oestrogen-dependent diseases and disorders
AU3980499A (en) 1998-05-11 1999-11-29 Endowment for Research in Human Biology, Inc., The Use of neomycin for treating angiogenesis-related diseases
US6669951B2 (en) 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US7229961B2 (en) 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
AU7586600A (en) 1999-09-14 2001-04-17 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
EP1232247A4 (en) 1999-11-23 2003-06-18 Gerhart Graupner MODULATION OF SIGNAL TRANSDUCTION
US20020031539A1 (en) 2000-08-30 2002-03-14 The Brigham And Women's Hospital, Inc. Oxidized forms of retinoic acid as ligands for peroxisome proliferator activated receptor gamma
US20020143062A1 (en) 2000-10-17 2002-10-03 Board Of Regents, The University Of Texas System Method to incorporate N-(4-hydroxyphenyl) retinamide in liposomes
US6408958B1 (en) * 2000-10-23 2002-06-25 Baker Hughes Incorporated Superabrasive cutting assemblies including cutters of varying orientations and drill bits so equipped
DK1349545T3 (da) 2000-12-05 2009-02-16 Los Angeles Childrens Hospital Farmaceutiske præparater af fenretinid med öget biotilgængelighed samt fremgangsmåder til anvendelse deraf
US20030032078A1 (en) 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
EP1390343B1 (en) 2001-05-29 2009-10-14 Chebigen Co., Ltd. Novel retinoid derivatives and an anti-cancer pharmaceutical composition comprising said compounds
CA2450562A1 (en) 2001-06-22 2003-01-03 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003003987A2 (en) 2001-07-06 2003-01-16 The Ohio State University Research Foundation Solid phase synthesis of arylretinamides
US6599891B2 (en) 2001-07-20 2003-07-29 Qlt Inc. Treatment of macular edema
US20030229062A1 (en) 2001-12-07 2003-12-11 The Regents Of The University Of California Treatments for age-related macular degeneration (AMD)
US20040014131A1 (en) 2002-07-09 2004-01-22 Pfizer Inc. Assay methods
WO2004041160A2 (en) 2002-10-30 2004-05-21 University Of Kentucky Research Foundation Methods and animal model for analyzing age-related macular degeneration
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
CA2509955A1 (en) 2002-11-29 2004-06-17 Gpc Biotech Ag Formulations useful against hepatitis c virus infections
SI21392A (sl) 2002-12-24 2004-06-30 Vinko Kunc Postopek za avtomatsko nastavitev ojačenja izpraševalnikovega sprejemnika v brezkontaktnem identifikacijskem sistemu
CA2513260C (en) 2003-01-31 2013-01-08 Childrens Hospital Los Angeles Oral compositions of fenretinide having increased bioavailability and methods of using the same
FI20030426L (fi) 2003-03-24 2004-09-25 Tomi Jaervinen Syklodekstriinikompleksit
US7178609B2 (en) * 2003-08-19 2007-02-20 Baker Hughes Incorporated Window mill and drill bit
WO2005059564A1 (en) 2003-12-11 2005-06-30 Beth Israel Deaconess Medical Center, Inc. Rbp4 in insulin sensitivity/resistance, diabetes, and obesity
WO2005077176A1 (en) 2004-02-11 2005-08-25 The Trustees Of Columbia University In The City Of New York Anthocyanin compounds and methods of use thereof
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
PL380611A1 (pl) * 2004-02-17 2007-02-19 President And Fellows Of Harvard College Postępowanie z zaburzeniami oftalmologicznymi, włącznie ze zwyrodnieniem plamki
CA2601278C (en) 2004-03-17 2014-06-10 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
PL2397133T3 (pl) 2004-06-18 2018-01-31 Univ Washington Pochodne retinalu i sposoby ich zastosowania do leczenia zaburzeń wzroku
PL1768657T3 (pl) 2004-06-23 2009-01-30 Revision Therapeutics Inc Sposoby i kompozycje do leczenia stanów ocznych za pomocą pochodnych retinylowych
US7286860B2 (en) 2004-07-23 2007-10-23 Dyna Llc Systems and methods for a comfortable wireless communication device
WO2006033734A2 (en) 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
JP2008519054A (ja) 2004-11-04 2008-06-05 シリオン セラピューティクス， インコーポレイテッド レチノール−レチノール結合タンパク質（ｒｂｐ）−トランスチレチン（ｔｔｒ）複合体の形成のモジュレーター
BRPI0520207A2 (pt) 2004-12-08 2012-09-25 Revision Therapeutics Inc uso de uma quantidade eficaz de um primeiro composto, e, medicamento sistemicamente formulado
UA81382C2 (en) 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding

Similar Documents

Publication Publication Date Title
JP2008504257A5 (enExample)
ES2411961T3 (es) Vehículos de suministro en forma de geoda
ES2286119T3 (es) Composicion de recubrimiento para enmascarar el sabor.
JP2012031131A5 (enExample)
ES2610411T3 (es) Sustrato sólido poroso disgregable para aplicaciones para el cuidado de la salud personal
ES2370729T3 (es) Forma farmacéutica hinchable que comprende goma gellan.
JP2013505928A5 (enExample)
JP2017165776A5 (enExample)
JP2016065086A5 (enExample)
IL164222A0 (en) Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
ATE543489T1 (de) Orale dosierformen mit progesteron und verwendungs- und herstellungsverfahren dafür
CN102970987A (zh) 通过施用包含长丝的个人保健制品来递送保健活性物质的方法
JP2016505022A (ja) ハチミツ鼻洗浄剤
JP2009538268A5 (enExample)
JP2015524444A5 (enExample)
JP2006515598A5 (enExample)
JP2010522698A5 (enExample)
WO2008008592A3 (en) Multi-particulate formulation having tramadol in immediate and controlled release form
CA2687741A1 (en) Stabilized amorphous forms of imatinib mesylate
JP2005213261A5 (enExample)
JP2011506587A5 (enExample)
JP2008516004A5 (enExample)
JP2013523676A5 (enExample)
WO2005053727A3 (en) Pharmaceutical compositions for bioactive peptide agents
JP2018199643A5 (enExample)